Immune cell senescence drives responsiveness to immunotherapy in melanoma.

ABSTRACT:

Background

Immunotherapy has significantly improved cancer treatment. However, it is not effective in all cancer patients, rendering the need to further delineate the differences among responders and non-responders at the molecular and cellular level. Unresponsiveness to immunotherapy has been attributed to dysfunctional immune cell states such as T-cell exhaustion and anergy, whereas the contribution of cellular senescence remains elusive. Herein, we have investigated the role of immune cell senescence in the response to checkpoint inhibitors in melanomas where these immunotherapies are applied as a first line treatment.

Methods

Two senescence detecting complementary approaches were utilized in a case control study we conducted. First, we implemented a senescence molecular

SUBMITTER: Pantelis P 

PROVIDER: S-EPMC12717699 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature